Eton Pharmaceuticals Inc Revenue Growth Rates (ETON), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Eton Pharmaceuticals Inc   (NASDAQ: ETON)
 

ETON's Revenue Growth by Quarter and Year

Eton Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ETON/growth
https://api.csimarket.com/api/v1/companies/ETON/fundamentals
https://api.csimarket.com/api/v1/companies/ETON/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ETON Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 57.93
2nd Quarter June 37.59
1st Quarter March 23.74
FY 119.26

ETONs Annual Revenue
Eton Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 79.74 millions
Eton Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 38.41 millions
Eton Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 31.06 millions
Eton Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 21.25 millions
Eton Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 21.83 millions




ETON Revenue third quarter 2026 Y/Y Growth Comment
Eton Pharmaceuticals Inc reported Revenue surge of 164.98% year on year in the third quarter 2026, to $ 57.93 millions, this is lower than Eton Pharmaceuticals Inc 's recent average Revenue surge of 1460.4%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 30 other companies have achieved higher Revenue growth. While Eton Pharmaceuticals Inc ' s Revenue doubling of 164.98% ranks overall at the positon no. 179 in the third quarter 2026.


ETON Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 164.98 %
2nd Quarter June 98.68 %
1st Quarter March 40.81 %
FY   -

Financial Statements
Eton Pharmaceuticals Inc 's third quarter 2026 Revenue $ 57.93 millions ETON's Income Statement
Eton Pharmaceuticals Inc 's third quarter 2025 Revenue $ 21.86 millions Quarterly ETON's Income Statement


ETON Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 54.1 %
2nd Quarter June 58.34 %
1st Quarter March 7.42 %
FY (Year on Year)   -


Back to ETON Growth rate Comparisons >> Back to ETON Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #31
Healthcare Sector #56
Overall #179

Revenue Y/Y Growth Statistics
High Average Low
15235 % 1460.4 % -82.35 %
(Dec 31 2021)  
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #31
Healthcare Sector #56
Overall #179
Revenue Y/Y Growth Statistics
High Average Low
15235 % 1460.4 % -82.35 %
(Dec 31 2021)  

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Eton Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
14587.65 % 588.48 % -100 %
(Mar 31 2021)  


ETON's III. Quarter Q/Q Revenue Comment
Eton Pharmaceuticals Inc achieved in the III. Quarter 2026 below company average Revenue jump of 54.1% quarter on quarter, to $ 57.93 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 15.54% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Eton Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 211.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #60
Overall #211
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #60
Overall #211
Revenue Q/Q Growth Statistics
High Average Low
14587.65 % 588.48 % -100 %
(Mar 31 2021)  


ETON's III. Quarter Q/Q Revenue Comment
Eton Pharmaceuticals Inc achieved in the III. Quarter 2026 below company average Revenue jump of 54.1% quarter on quarter, to $ 57.93 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 15.54% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Eton Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 211.


Eton Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 105.28
Y / Y Revenue Growth (TTM) 79.77 %
Year on Year Revenue Growth Overall Ranking # 351
Seqeuential Revenue Change (TTM) 21.55 %
Seq. Revenue Growth (TTM) Overall Ranking # 657


Cumulative Revenue growth Comment
Although Eton Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 502.3% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 79.77% year on year, from 79.46% in Mar 31 2026.

In the Healthcare sector 94 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 266 to 351.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 62
Healthcare Sector # 95
Overall # 351

Revenue TTM Y/Y Growth Statistics
High Average Low
6576.45 %
 502.3 %
-2.66 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 62
Sector # 139
S&P 500 # 657
Cumulative Revenue growth Comment
Although Eton Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 502.3% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 79.77% year on year, from 79.46% in Mar 31 2026.

In the Healthcare sector 94 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 266 to 351.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 62
Healthcare Sector # 95
Overall # 351

Revenue TTM Y/Y Growth Statistics
High Average Low
6576.45 %
502.3 %
-2.66 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 62
Sector # 139
S&P 500 # 657




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ETON's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Aligos Therapeutics Inc 281.92%$ 281.916 millions
Clene Inc 273.33%$ 273.333 millions
Recursion Pharmaceuticals Inc 258.49%$ 258.493 millions
Nuvation Bio Inc 251.98%$ 251.977 millions
Seastar Medical Holding Corp246.99%$ 246.995 millions
Prime Medicine Inc 243.92%$ 243.918 millions
Urogen Pharma Ltd 227.16%$ 227.161 millions
Dianthus Therapeutics Inc 205.56%$ 205.556 millions
Bridgebio Pharma Inc 192.60%$ 192.602 millions
Bicycle Therapeutics Plc190.24%$ 190.242 millions
Gossamer Bio Inc 189.09%$ 189.085 millions
Alpha Cognition Inc.173.75%$ 173.751 millions
Eton Pharmaceuticals Inc 165.04%$ 165.042 millions
Sera Prognostics Inc 162.50%$ 162.500 millions
Volitionrx Limited157.28%$ 157.283 millions
Neuraxis Inc 149.92%$ 149.922 millions
Pluri Inc 140.19%$ 140.190 millions
Camp4 Therapeutics Corporation138.87%$ 138.868 millions
Sonida Senior Living Inc 114.40%$ 114.402 millions
Verastem Inc 113.59%$ 113.592 millions
Hyperfine Inc 109.27%$ 109.270 millions
Pelthos Therapeutics Inc 107.87%$ 107.872 millions
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions


About Eton Pharmaceuticals Inc Revenue Growth Rates (ETON), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Eton Pharmaceuticals Inc (CIK 1710340).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001710340-26-000009
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Eton Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.